BIONTECH SE SPON. ADRS 1
Commented by Armin Schulz on March 18th, 2025 | 07:00 CET
Bayer, Vidac Pharma, BioNTech – Making money with biotech and pharmaceutical innovations
More and more investors are betting on companies that are leaving traditional therapeutic paths to rethink cancer, chronic inflammation, or nutritional issues. While some corporations struggle with their balance sheets due to mountains of debt and patent expirations, others are quietly developing technologies that crack the metabolic code of diseases. Whether anti-aging tests from saliva samples, mRNA-based cancer cocktails, or active ingredients that overcome the blood-brain barrier – the stock market rewards those who combine research success with strategic risk-taking. But which companies have what it takes to develop the blockbusters of tomorrow? Let's take a closer look at three companies.
Read
Commented by Armin Schulz on March 3rd, 2025 | 07:40 CET
Novo Nordisk, NetraMark Holdings, BioNTech – How three pioneers are paving the way for tomorrow's medicine
On January 6, 2025, the FDA announced new guidelines for AI-powered clinical trials to accelerate the approval of life-saving therapies. This has put a spotlight on companies that combine technology and biotechnology. They are addressing pressing challenges: chronic widespread diseases, complex cancer progression, and inefficient drug development. With artificial intelligence, mRNA platforms, and strategic alliances, they are revolutionizing not only therapies but also the way pharmaceutical companies research and scale up. However, the road is rocky – regulatory hurdles, supply bottlenecks, and the race for the next blockbuster shape their stories. Who are the players disrupting billion-dollar markets with innovative approaches?
Read
Commented by André Will-Laudien on February 27th, 2025 | 07:50 CET
Attention – Biotech is taking off! Evotec, Vidac Pharma, BioNTech, and Novo Nordisk in focus
With new index highs and huge daily trading volumes, the biotech sector has been back in the spotlight for several weeks. At Evotec, the personnel merry-go-round continues, while BioNTech has announced an acquisition in the oncology field. After the big crash in Novo Nordisk shares, the first share buybacks are now taking place, but growth rates have been revised downwards. Vidac Pharma has just completed a roadshow and will present its latest progress at the Sachs Health Science CEOs Forum in Zurich. Share prices across the sector appear to have turned in the last quarter. It is now time for investors to take a closer look again. We offer a few insights.
Read
Commented by Fabian Lorenz on February 20th, 2025 | 07:30 CET
Multiplier potential with AI newcomer NetraMark! Palantir and BioNTech in one share!
"Game changer!" "Quantum leap!" "Revolution!" Experts use numerous superlatives to describe the possibilities of Artificial Intelligence (AI) in medicine. What is certain is that AI offers tremendous potential to develop new medications faster and more cost-effectively. Pharmaceutical companies can save billions, and patients can be cured more quickly. The market for AI in medicine is expected to see significant double-digit growth rates in the coming years. NetraMark Holdings aims to profit from this megatrend. The AI specialist is on the verge of a breakthrough and is starting 2025 with a software update, an important partnership, and reinforcements in top management. The share price has jumped but remains a hidden gem and is anything but expensive. There is significant upside potential!
Read
Commented by Fabian Lorenz on February 13th, 2025 | 07:10 CET
ACQUISITION?! Renk, BioNTech, and Biotech Highflyer Vidac Pharma
Is Renk about to be taken over? Quite possible. The Company, known for its transmissions for the Leopard tank, has a new major shareholder. And it turns out to be none other than KNDS – the maker of the Leopard 2 tank. The Renk share price reacted with a jump of 10%. Is there more to come? Vidac Pharma is also frequently mentioned as a potential takeover candidate. Like BMW, the Company is working on a "new class". But in this case, it is to save human lives. To this end, last year's biotech highflyer aims to revolutionize cancer treatment. Experts believe that a multiplication of the share price is possible. BioNTech is also fighting cancer. In addition to its own research, the German company is strategically focusing on acquisitions. Another one has just been completed. What is next?
Read
Commented by Armin Schulz on January 22nd, 2025 | 07:00 CET
Evotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer
It has been clear for some time that cancer can affect anyone, and not just since King Charles and Princess Kate made their battles with cancer public. The market is growing, and today, revenues in this area are already in the billions. This is driven by an aging population and increasingly unhealthy lifestyles. The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market.
Read
Commented by André Will-Laudien on January 6th, 2025 | 07:00 CET
Biotech-Rally 2025: Evotec, BioNTech, Vidac Pharma, Pfizer and Bayer are on the buy list
For two years, there was almost no movement in the biotech sector. Not even the trend of falling interest rates that began in 2024 could persuade investors to make larger investments. Meanwhile, AI and high-tech stocks continued to perform well, driving the Nasdaq 100 index up by over 30%. However, in the last quarter of 2024, some bombed-out life sciences stocks saw significant markups, and new takeover rumours also began circulating. Whether the sentiment can continue to rise in the coming weeks is something we will explore further. Let's take a closer look at our top picks for 2025.
Read
Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET
Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.
Read
Commented by Armin Schulz on December 2nd, 2024 | 07:20 CET
Evotec, Vidac Pharma, BioNTech – Cancer research: The gold mine in the portfolio
Investing in publicly traded companies active in oncology research offers promising returns and long-term stability. The oncology market is one of the fastest-growing sectors in healthcare and benefits from an ever-increasing demand for innovative and personalized cancer therapies. Advances such as CAR-T cell therapies and antibody-drug conjugates are revolutionizing treatment options and creating new opportunities for companies and investors. At the same time, the sector is characterized by a low dependence on economic fluctuations and a high level of dynamism in mergers and acquisitions. With long-term trends such as an aging population, this market offers solid prospects for investors. We take a look at three promising companies.
Read
Commented by Fabian Lorenz on November 28th, 2024 | 07:30 CET
PRICE SURGE or SELL-OFF: Buy BioNTech? Is Evotec on the verge of a slump? BioNxt Solutions share on the brink of a breakout?
Price opportunity with BioNxt! If the innovative biotech stock breaks out of its sideways movement since September, a quick 50% gain could be possible. In any case, things are going well operationally. The Company is developing next-generation drug delivery systems. The Evotec share is not for the faint-hearted. After the price jump following the takeover offer, a sharp drop followed. Analysts see the fair value of the biotech company well below the current price. Will takeover speculation continue? The BioNTech share has avoided slipping below EUR 100. Analysts view the data on the breast cancer candidate positively and recommend buying.
Read